Blood pressure drugs halt pancreatic cancer cell growth, researchers find

Researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia are inching closer to understanding how common blood pressure medications might help prevent the spread of pancreatic cancer. They have found in the laboratory that one type of pressure-lowering drug called an angiotensin receptor blocker inhibits pancreatic cancer cell growth and causes cell death.

In earlier work in the laboratory, Hwyda Arafat, M.D., Ph.D., associate professor of Surgery at Jefferson Medical College, and her team showed that angiotensin receptor blockers may help reduce the development of tumor-feeding blood vessels, a process called angiogenesis. Other studies have linked a lower incidence of cancer with the use of angiotensin blocking therapies. Such drugs, she says, may become part of a novel strategy to control the growth and spread of cancer.

One of these drugs – AT1R (Ang II type 1 receptor) blockers – inhibit the function of the
hormone angiotensin II (Ang II) in the pancreas. The receptor is expressed in pancreatic
cancer cells. Ang II increases the production of VEGF, a vascular factor that promotes blood vessel growth in a number of cancers. High VEGF levels have been correlated with poor cancer prognosis and early recurrence after surgery. Dr. Arafat’s research team has shown that AngII indirectly causes VEGF expression by increasing AT1R expression.

Dr. Arafat’s group explored the effects of blocking AT1R on the pancreatic cancer cell reproductive cycle and programmed cell death, or apoptosis, and the mechanisms involved. It found that blocking AT1R inhibited pancreatic cancer cell growth and promoted cell death. “This happens through inducing the activity of the gene p53, which controls programmed cell death, and also by inhibiting anti-cell death pathways such as those involving the gene bcl-2.” The team reports its findings April 14, 2008 at the annual meeting of the American Association for Cancer Research in San Diego.

The researchers also found that blocking AT1R affects p21, a gene that regulates the cell cycle. “We found that blocking this receptor can cause cell cycle arrest,” she notes.

“This is really exciting because the role of this receptor has never been known,” Dr. Arafat says. “It’s never been connected to cell division or apoptosis. We’re also now further exploring the mechanisms involved. The exciting thing is that this receptor already has so many available pharmaceutical blockers on the market.” Ultimately, the group hopes to be able to test these agents in human trials, she says.

Source: Thomas Jefferson University

Related stories:

Battling cancer, one cell at a time
New research suggests that the identification and examination of key cell signaling events required for initiation and progression of cancer might be best accomplished at the single cell level. The research, published by Cell Press in the October issue of the journal Cancer Cell, provides new insight that may lead to better diagnosis and treatment of some complex cancers.
Net widens as more proteins implicated in cancer spread
(PhysOrg.com) -- Authorities are on the lookout for 64 proteins believed to have been talking to well-known cancer kingpin urokinase plasminogen activator receptor (a.k.a uPAR).
Study shows immune system can hurt as well as help fight cancer
Researchers at the University of Pennsylvania School of Medicine have found that some proteins of the immune system can promote tumor growth. Investigators found that instead of fighting tumors, the protein C5a, which is produced during an immune response to a developing tumor, helps tumors build molecular shields against T-cell attack. These findings appeared online this week in Nature Immunology.
Deactivating a cancer growth promoter
Three enzymes called phosphatases that shut down a molecule called SRC-3 (steroid receptor coactivator 3) could provide a new pathway for fighting cancer, particularly tumors of the breast and prostate, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal Molecular Cell.
New predictive tool can help determine treatment of breast cancer patients
A new predictive measurement, called a PEPI score, could bring good news to many women diagnosed with early stage breast cancer — a low PEPI (preoperative endocrine prognostic index) score could show that they have little risk of relapse and can safely avoid chemotherapy after surgery.
Variant of vitamin D receptor gene linked to melanoma risk
A new analysis indicates an association between a gene involved in vitamin D metabolism and skin cancer. Published in the November 1, 2008 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that individuals with certain variants in a vitamin D-related gene, called BsmI, may be at an increased risk of developing melanoma.
New technique sees into tissue at greater depth, resolution
By coupling a kicked-up version of microscopy with miniscule particles of gold, Duke University scientists are now able to peer so deep into living tissue that they can see molecules interacting.
New results help predict treatment response in colorectal cancer
Genetic testing can identify a group of patients with advanced colorectal cancer who are likely to survive on average twice as long if treated with the drug cetuximab, late breaking results show.

News discussion:

Medicine & Health news